| Budget Amount *help |
¥3,400,000 (Direct Cost: ¥3,400,000)
Fiscal Year 2001: ¥900,000 (Direct Cost: ¥900,000)
Fiscal Year 2000: ¥2,500,000 (Direct Cost: ¥2,500,000)
|
|---|
| Research Abstract |
Case-control studies on the association between breast cancer risk and genetic polymorphisms mainly relating to estrogens were conducted for patients (239 breast cancer patients and 186 non-cancer controls) of Aichi Cancer Center Hospital of Aichi Cancer Center Hospital. After written informed consent for genotyping was obtained, the participants were asked to provide lifestyle information and a peripheral blood sample. Genotyping was conducted mainly with PCR-RFLP. In 2000-2001, the association of breast cancer risk with estrogen-related polymorphisms ; cytochrome p450 17 (CYP17) C-34T, cytochrome p450 19 (CYP19) Trp39Arg, catechol-O-methyltransferase (COMT) Val158Met, and interleukin (IL) 1B C-31T, obesity-related polymorphisms! beta-adrenoceptor 2 (BAR2) Gln27Glu and beta-adrenoceptor 3 (BAR3) Trp64Arg, carcinogen-metabolism-related polymorphism ; NAD(P)H:qmnone oxidoreductase 1 (NQO1) C609T, and carcinogenesis-related polymorphisms; p53 Arg72Pro and transforming growth factor (TGf) B1 T29C were examined. No associations were observed for CYP17 C-34T, CYP19 Trp39Arg, COMT Val158Met, BAR3 Trp64Arg, and NQO1 C609T. Concerning BAR2 Gln27Glu, a significant risk reduction was observed among women harboring 27Glu who gave the first birth at age 25 years or younger. The odds ratio for IL-B -31TT genotype relative to -31CC genotype was significantly reduced (OR=0.54, 95 % confidence interval, 0.33-0.90), especially among postmenopausal women (OR=0.29, 0. 14-0.61).
|
